Cibus, Inc. (CBUS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. Financial performance shows cost reductions but a rising net loss, which is concerning. Product development and business updates are promising, with commercialization plans and regulatory advancements. However, Q&A reveals concerns about market adoption risks and lack of specific guidance on royalties. While the company has made progress in partnerships and regulatory approvals, the financial health and uncertain revenue growth temper the outlook, leading to a neutral sentiment.
Key Financial Performance
Cash and Cash Equivalents $9.9 million as of December 31, 2025. This was supported by a $22.3 million capital raise in January 2026, which extended the company's financial runway.
Operating Expenses Reduction Reduced by approximately $10 million across R&D and SG&A for the full year of 2025 due to cost-saving initiatives.
Research and Development Expense $9.4 million for Q4 2025, compared to $12.4 million in Q4 2024, a $3 million decrease due to cost reduction initiatives.
Selling, General and Administrative Expense $5.1 million for Q4 2025, compared to $6.8 million in Q4 2024, a $1.7 million decrease due to cost reduction initiatives.
Royalty Liability Interest Expense $9.4 million for Q4 2025, compared to $8.2 million in Q4 2024, a $1.2 million increase due to recognition of interest expense on the royalty liability.
Net Loss $31.9 million for Q4 2025, compared to $25.8 million in Q4 2024, an increase driven by fair value adjustments of liability-classified common warrants.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Rice Program: 7 rice customers represent over $200 million in potential annual royalty opportunities. Initial market entry in Latin America is on track for 2027, followed by U.S. expansion in 2028 and entry into India and Asia closer to 2030. Progress includes a nonbinding LOI with Interoc for commercialization in Latin America and partnerships with CIAT and Colombian seed companies.
Sustainable Ingredients: First customer payment received for biofragrance program. Pre-commercial pilot runs completed for two biofragrance products, targeting commercial scale production later this year. Potential $20 million to $40 million annual royalty opportunity.
Geographic Expansion: Expanding rice program to Latin America, India, Asia, and potentially Brazil and Argentina. Partnerships and regulatory approvals are paving the way for market entry in these regions.
Regulatory Developments: EU reached political agreement on new genomic techniques legislation, opening approximately 100 million acres of opportunity. Positive regulatory developments in the U.K., U.S., Ecuador, and Peru are accelerating global commercial conversations.
Cost Reduction: Reduced operating expenses by approximately $10 million in 2025. Consolidated operations into San Diego headquarters and reduced workforce to lower annual net cash usage to $30 million or less in 2026.
Technology Advancements: Improved editing efficiency in rice and expanded trait development capabilities across multiple crops. Leveraging AI and machine learning for faster and more precise gene editing.
Commercial Model Evolution: Shifting from single trait licensing to broader genomic editing relationships with seed companies. Exploring outsourced gene editing partnerships in high-growth markets like India, Asia, and Latin America.
Regulatory Engagement: Actively engaging with global regulators to shape gene editing frameworks, enhancing market readiness and accelerating adoption.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Uncertainty: The company faces risks related to regulatory frameworks for gene editing, particularly in Europe where the EU's genomic techniques legislation is still pending a plenary vote. Delays or unfavorable outcomes could impact market entry and commercial opportunities.
Financial Sustainability: Cibus reported a net loss of $31.9 million for Q4 2025 and has limited cash runway extending only into late Q3 2026. This creates financial pressure and dependency on future financing or revenue milestones to sustain operations.
Market Entry Delays: The company’s rice program, a key revenue driver, is not expected to generate revenue until 2027 in Latin America and 2028 in the U.S., with India and Asia targeted for 2030. Delays in market entry could impact financial performance.
Supply Chain and Operational Risks: The company has consolidated operations and reduced workforce, which may create operational challenges or inefficiencies as it scales its programs.
Competitive Pressures: Cibus operates in a highly competitive gene editing market. The need to maintain technological leadership and secure partnerships is critical to its success.
Economic and Market Risks: The company’s reliance on royalty-based revenue models exposes it to risks from market adoption rates and economic conditions in target regions like Latin America, India, and Asia.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections: Cibus anticipates significant revenue generation from its rice program, with potential annual royalties of $200 million from 7 rice customers across the United States and Latin America. Initial market entry is expected in Latin America in 2027, followed by U.S. expansion in 2028 and entry into India and Asia closer to 2030.
Market Trends and Expansion: Cibus is targeting high-growth markets such as India, Asia, and Latin America for outsourced gene editing services. The company is also pursuing access to the Brazilian and Argentinian markets, which represent substantial acreage opportunities.
Sustainable Ingredients Program: Cibus is targeting commercial scale production of biofragrance products later in 2026, with potential annual royalties of $20 million to $40 million. The company is also exploring additional fragrances using the same yeast platform.
Regulatory Developments: The EU's political agreement on new genomic techniques legislation and regulatory acceptance in India are expected to accelerate commercial opportunities. The EU plenary vote in late April 2026 is a key milestone.
Operational Goals: Cibus aims to finalize a definitive commercial agreement with Interoc by late 2026 and expand its rice program to include additional trait stacking for broader weed management and crop protection.
Technological Advancements: The company is leveraging AI and machine learning to enhance editing efficiency and scalability, enabling broader partnerships and faster trait development.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Does the EU NGT framework change the company's approach to CapEx for the canola WOSR program?
A:The EU regulatory progress is seen as a watershed moment, opening up opportunities in Europe, which has 100 million acres of greenfield opportunity. The company has developed an efficient platform and production system for Winter Oilseed Rape, aligning with the EU regulatory framework. This progress has generated interest from major seed companies in Europe and globally.
Q:What are the next steps to commercialization in Latin America for rice, and what milestones will be reported?
A:The company has built a process for editing elite genetics in rice, with partnerships in Latin America. The first step involves editing elite genetics within 12-15 months. A letter of intent with Interoc for commercialization of HT3 and HT1 traits in Ecuador and Colombia has been signed, targeting a 2027 launch. Milestones include progress on chemical registration and trait work in elite genetics.
Q:What is the trend line for the total number of acres touched by the company's technology from 2025 to 2027?
A:The company targets 5-7 million acres in the Americas over the first three years, with potential annual royalties of over $200 million. Expansion into the Indian market, with 120 million acres, is expected to generate royalties by 2029-2030.
Q:What is the maximum throughput for gene edits as a service without significant R&D expense increases?
A:The company has built a scalable system combining cell biology, automation, and AI, allowing for efficient processing of genetics. Modest team increases can manage multiple crops and lines, with funding from partnerships covering editing expenses.
Q:What royalty rates are being discussed for gene edits as a service, and how has this changed over time?
A:The company emphasizes speed and scalability, delivering edits in elite genetics within a year. This accelerates value realization, making royalty negotiations favorable. The focus is on sharing value with farmers and seed companies.
Q:What is the scale of fragrances the company could work on in one year at the current cost run rate?
A:The company has been working on a few fragrances and sees potential to scale quickly. There are about 17 fragrances identified for development, with a focus on building out the process and expanding opportunities.
Q:Why did collaboration revenue and earnings come in below consensus in the fourth quarter?
A:The shortfall was due to timing issues related to revenue recognition linked to time spent by personnel. Cash flow remains on track, and upcoming numbers are expected to align with projections.
Q:What is the potential to expand with the current biofragrance customer, and what conversations are happening with other potential customers?
A:The company sees broad opportunities in the fragrance sector and is working with a strong partner to build out to full commercial scale. Expansion opportunities with the current partner and other potential customers are being explored.
Q:How is the company thinking about financing and flexibility with current funds into late 2026?
A:The company has focused on streamlining operations, consolidating facilities, and leveraging automation and AI to manage cash burn. A January financing transaction has extended funds into late Q3 2026, allowing focus on near-term revenues in rice and fragrance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the royalty rates being discussed for gene edits as a service, using general terms like 'favorable' and emphasizing value sharing without numerical specifics.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Cibus gene
Co Founder
EU agreement
India Asia
Interoc
Leaf Spot
Light Leaf
PBO filing
Peru
RTDS platform
access
agreement technique
capability opportunity
collaboration
consortium
conversation
crop portfolio
editing capability
edits Cibus
fertilizer
filing Defra
framework
genetics edits
government technology
herbicide trait
liability
licensing
material
partner editing
planting
platform gene
potential
program value
raise
readiness
relationship
royalty opportunity
runway
scale
technology partner
CBUS Transcript
Cibus, Inc. (CBUS) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call summary shows positive financial performance with increased revenue, gross margin, and net income. However, the lack of discussion on strategic initiatives, operational updates, and risk management creates uncertainty about future growth. The Q&A session did not provide additional insights, and no significant market-moving announcements were made. Overall, the financial health is solid, but the absence of strategic clarity limits the potential for a strong stock price reaction, leading to a neutral prediction.
Cibus, Inc. (CBUS) Q4 2025 Earnings Call Transcript
Unknown3-17
The earnings call presents a mixed picture. Financial performance shows cost reductions but a rising net loss, which is concerning. Product development and business updates are promising, with commercialization plans and regulatory advancements. However, Q&A reveals concerns about market adoption risks and lack of specific guidance on royalties. While the company has made progress in partnerships and regulatory approvals, the financial health and uncertain revenue growth temper the outlook, leading to a neutral sentiment.
Cibus, Inc. (CBUS) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call summary indicates a positive outlook with significant cost reductions, improved net loss, and strategic focus on future revenue streams, particularly from rice herbicide traits and biofragrance programs. The Q&A reveals optimism about R&D collaborations, regulatory progress, and market potential, despite some uncertainties in financing specifics. The strong potential for royalty revenue and commercial expansion, coupled with reduced expenses, suggests a positive stock movement over the next two weeks.
Cibus, Inc. (CBUS) Q2 2025 Earnings Call Transcript
Unknown8-15
The earnings call shows mixed signals: a slight revenue increase and reduced expenses are positives, but reliance on partner-funded programs and economic uncertainties pose risks. The Q&A reveals cautious optimism, with management avoiding specifics on key projects. The recent public offering improved cash reserves, but the stock may remain neutral due to uncertainties and lack of strong catalysts.
CBUS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
